Developmental Research Program

计划摘要 孢子指南要求勤奋努力确定并资助试点项目，以探索创新想法 可能最终会降低肺癌的发病率和发病率或提高生存率。UTSW和 UTMDACC在通过孢子获得和管理发展资金方面有重要记录 外部资金，并发现孢子发展研究计划是最有价值的 并且产孢子成分。UTSW在管理发展方面有25年的记录 用于癌症研究的资金。这些资金可以通过美国癌症协会(ACS)机构获得 格兰特IN-142。美国癌症协会的资金必须分配给癌症研究的新研究者，这些研究者提出了 试点项目特别有价值，而且有可能通过同行审查获得国家赠款支持。 机制。在UTMDACC，临床每年提供超过1,000,000美元的开发资金 为临床和基础科学学院的发展项目提供收入。此外，UTMDACC联合PI (Jack Roth)管理了一个创新癌症疗法的开发研究项目，该项目由 W.M.凯克基金会使用外部同行审查机制。这笔额外的资金强调了 UTMDACC致力于翻译研究，并为发展项目提供额外支持。 作为UTSW和UTMDACC对孢子的重新承诺的一部分，从 德克萨斯州烟草和解基金和其他机构资金将从UTSW获得 (50,000美元)和UTMDACC(100,000美元)，用于肺癌孢子发育研究项目。 肺癌创新研究思路的发展在很大程度上取决于能否获得 试点项目资金来源灵活。孢子发育研究计划的目的是 鼓励和开发实验室研究项目，这些项目将导致临床上可验证的假说 降低肺癌发病率或发病率或提高存活率的潜力。实验室和临床都有 研究项目只要是翻译性的，就有资格获得资助。孢子的一部分 NCI预算(直接成本100,000美元，发展项目50,000美元，职业发展50,000美元 项目--见职业发展科)将按年分配，以支持两个UTSW的试点项目 和UTMDAcc。这些拨款符合《孢子准则》对预算的要求。然而，我们 压力，这将与UTSW和MDACC每年150,000美元的机构承诺(UTSW)相结合 50,000美元和MD Anderson癌症中心100,000美元)，这相当于150,000美元的发展项目 从孢子身上加5万美元..因此，NCI和机构的UTSW+MDACC合计 肺癌孢子发育项目的资金为200,000美元。这类资金将仅限于 然而，每个项目每年的最高限额为50,000美元，但大多数奖项是每个项目25,000美元，总计 每年授予的~8个开发项目。资助期限为一年，可续期一年 额外的一年。虽然预算将10万美元的直接成本平均分配给这两个机构，但 孢子发展计划将根据业绩分配资金，使用一项 后面的部分。这些项目可能而且经常涉及UTSW和UTMDAccess之间的合作 调查人员特别考虑到孢子资源的利用，如孢子病理核心B， 生物统计核心C和生物信息学核心D，这大大增强了 发展奖。这些项目也可能授予其他机构的调查人员。例如 德克萨斯大学奥斯汀分校的安德鲁·艾灵顿博士因获得RNA适配子而获得开发奖 专为肺癌而设。

PROGRAM SUMMARY SPORE guidelines mandate diligent efforts to identify and fund pilot projects to explore innovative ideas that may eventually reduce the incidence and morbidity or increase the survival of lung cancer. Both UTSW and UTMDACC have significant records in obtaining and administering development funds via the SPORE and outside funds and have found the SPORE Developmental Research Program to be one of the most valuable and productive of the SPORE components. UTSW has a -25-year track record of administering developmental funds for cancer research. These funds are available through the American Cancer Society (ACS) Institutional Grant IN-142. The ACS funds must be distributed to new investigators in cancer research whose proposed pilot projects are especially worthy and likely to gain national grant support through the peer-review mechanism. At UTMDACC, more than $1,000,000 in development funds is made available yearly from clinical revenues to both clinical and basic science faculty for development projects. In addition, the UTMDACC Co-Pi (Jack Roth) has administered a developmental research program in innovative cancer therapies funded by the W. M. Keck Foundation using an external peer-review mechanism. This additional funding underscores UTMDACC's commitment to translational research and provides additional support for development projects. As part of the UTSW and UTMDACC renewed commitment to the SPORE, an additional $150,000 from Texas Tobacco Settlement Funds and other institutional funds will be made available from UTSW ($50,000) and UTMDACC ($100,000) for Lung Cancer SPORE Developmental Research Projects. The development of innovative research ideas in lung cancer is critically dependent on the availability of flexible funding for pilot projects. The purpose of the SPORE Developmental Research Program is to encourage and develop laboratory research projects that will result in clinically testable hypotheses with potential for reducing lung cancer incidence or morbidity or for increasing survival. Both laboratory and clinical research projects are eligible for funding, provided they are translational in nature. A proportion of the SPORE NCI budget ($100,000 in direct costs, $50,000 to Developmental Projects and $50,000 to Career Development Projects - see Career Development Section) will be allocated yearly to support pilot projects at both UTSW and UTMDACC. These allocations fulfill the SPORE Guideline requirements for budgeting. However, we stress, this will be combined with a yearly UTSW and MDACC institutional commitment of $150,000 (UTSW $50,000 and MD Anderson Cancer Center $100,000) which represent $150,000 for Developmental Projects plues $50,000 from the SPORE.. Thus, the combined UTSW + MDACC total from NCI and Institutional funds for Lung Cancer SPORE Developmental Projects is $200,000. Such funding will be limited to a maximum of $50,000 per year per project, however, most of the awards are for ~$25,000 per project for a total of ~8 Developmental Projects awarded per year. Funding will be for one year and will be renewable for one additional year. While the budget divides the $100,000 in direct costs equally between the two institutions, the SPORE Developmental Program will allocate funding based on merit using the review process described in a later section. These projects may, and often involve collaborations between UTSW and UTMDACC investigators particularly given the use of SPORE resources such as the SPORE Pathology Core B, Biostatistics Core C, and Bioinformatics Core D, which greatly augment the translational capability of the Developmental Awards. These projects may also be awarded to investigators at other institutions. For example Dr. Andrew Ellington on the faculty of UT Austin received a Development award for deriving RNA aptamers specific for lung cancer.